Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Bolla

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
Antibiotics (Basel, Switzerland)|April 26, 2024
Design and Synthesis of Novel Amino and Acetamidoaurones with Antimicrobial ActivitiesAttilio Di Maio, Hamza Olleik, Elise Courvoisier-Dezord, et al.
European Urology|September 5, 2016
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerPhilip Cornford, Joaquim Bellmunt, Michel Bolla, et al.
Health and Quality of Life Outcomes|May 12, 2017
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancerMarieke van Leeuwen, Jacobien M Kieffer, Fabio Efficace, et al.
The Lancet. Oncology|January 21, 2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised studyJean-François Bosset, Gilles Calais, Laurent Mineur, et al.
International Journal of Radiation Oncology, Biology, Physics|October 19, 2005
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patientsMahmut Ozsahin, Richard W Tsang, Philip Poortmans, et al.
The New England Journal of Medicine|June 12, 2009
Duration of androgen suppression in the treatment of prostate cancerMichel Bolla, Theodorus M de Reijke, Geertjan Van Tienhoven, et al.
JAMA Oncology|October 17, 2018
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysisAmar U Kishan, Xiaoyan Wang, Wendy Seiferheld, et al.
Lancet (London, England)|October 23, 2012
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)Michel Bolla, Hein van Poppel, Bertrand Tombal, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 23, 2018
Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network studyAlessandra Franzetti Pellanda, Berardino De Bari, Elisabeth Deniaud-Alexandre, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2008
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'Sandra Collette, Laurence Collette, Tom Budiharto, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
Antibiotics (Basel, Switzerland)|April 26, 2024
Design and Synthesis of Novel Amino and Acetamidoaurones with Antimicrobial ActivitiesAttilio Di Maio, Hamza Olleik, Elise Courvoisier-Dezord, et al.
European Urology|September 5, 2016
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate CancerPhilip Cornford, Joaquim Bellmunt, Michel Bolla, et al.
Health and Quality of Life Outcomes|May 12, 2017
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancerMarieke van Leeuwen, Jacobien M Kieffer, Fabio Efficace, et al.
The Lancet. Oncology|January 21, 2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised studyJean-François Bosset, Gilles Calais, Laurent Mineur, et al.
International Journal of Radiation Oncology, Biology, Physics|October 19, 2005
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patientsMahmut Ozsahin, Richard W Tsang, Philip Poortmans, et al.
The New England Journal of Medicine|June 12, 2009
Duration of androgen suppression in the treatment of prostate cancerMichel Bolla, Theodorus M de Reijke, Geertjan Van Tienhoven, et al.
JAMA Oncology|October 17, 2018
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysisAmar U Kishan, Xiaoyan Wang, Wendy Seiferheld, et al.
Lancet (London, England)|October 23, 2012
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)Michel Bolla, Hein van Poppel, Bertrand Tombal, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 23, 2018
Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network studyAlessandra Franzetti Pellanda, Berardino De Bari, Elisabeth Deniaud-Alexandre, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2008
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'Sandra Collette, Laurence Collette, Tom Budiharto, et al.
Pageof 16